Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
CAMBRIDGE, MA / ACCESSWIRE / March 24, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will present its Vaccines Day for analysts and investors at 8:00 a.m. ET on Tuesday, April 11, 2023.
马萨诸塞州剑桥/ACCESSWIRE/2023 年 3 月 24 日/ 开创信使RNA（mRNA）疗法和疫苗的生物技术公司Moderna, Inc.（纳斯达克股票代码：MRNA）今天宣布，它将在美国东部时间2023年4月11日星期二上午8点为分析师和投资者举办疫苗日。
Moderna's Vaccines Day will include presentations from management and key opinion leaders (KOLs) on Moderna's mRNA vaccines and key considerations for vaccine development. A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for one year following the presentation.
Moderna的疫苗日将包括管理层和主要意见领袖（KOL）就Moderna的mRNA疫苗和疫苗开发的关键考虑因素发表演讲。网络直播将在moderna网站investors.modernatx.com的投资者部分的 “活动和演讲” 下提供。网络直播的重播将在演讲结束后在 Moderna 的网站上存档一年。
About Moderna
关于 Moderna
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID pandemic.
自成立以来的十多年中，Moderna已从一家推进信使RNA（mRNA）领域项目的研究阶段公司转变为一家拥有七种模式的多样化疫苗和疗法临床组合、广泛的知识产权组合和综合制造设施的企业，可进行大规模的快速临床和商业化生产。Moderna 与广泛的国内外政府和商业合作者保持着联盟，这使我们得以追求开创性科学和快速扩大制造规模。最近，Moderna的能力汇集在一起，允许授权使用和批准针对COVID疫情的最早、最有效的疫苗之一。
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit
Moderna 的 mRNA 平台建立在基础和应用 mRNA 科学、递送技术和制造的持续进步基础上，允许开发传染病、免疫肿瘤学、罕见疾病、心血管疾病和自身免疫性疾病的疗法和疫苗。在过去的八年中，Moderna被Science评为最佳生物制药雇主。要了解更多信息，请访问
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
投资者：
Lavina Talukdar
高级副总裁兼投资者关系主管
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
来源： Moderna, Inc.
译文内容由第三方软件翻译。